Applied dna announces receipt of linea(tm) dna follow-on order for cancer diagnostic application

Stony brook, ny / accesswire / november 28, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced the receipt of a follow-on order for linea™ dna valued above the mid-six figures. the order was placed under a long-standing supply agreement for the bulk manufacture of linea dna (non-therapeutic) for a global manufacturer of in vitro diagnostics (ivd).
APDN Ratings Summary
APDN Quant Ranking